feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

Counterfeit rabies vaccine alert issued

trending

India U19 World Cup squad

trending

Gambhir's fate depends on T20

trending

Jurrien Timber injury unites Arsenal

trending

Nigeria vs Tunisia AFCON match

trending

Juventus faces Pisa Saturday

trending

Kartik Aaryan film earns crores

trending

Spalletti explains Juventus changes

trending

De'Aaron Fox out versus Jazz

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Business and Economy / FactSet Stock Plummets Amidst Mixed Earnings

FactSet Stock Plummets Amidst Mixed Earnings

27 Nov

•

Summary

  • FactSet stock has dropped 44.3% over the last year.
  • The company reported mixed Q4 earnings with revenue growth but declining margins.
  • Analysts maintain a 'Hold' consensus rating on FactSet shares.
FactSet Stock Plummets Amidst Mixed Earnings

FactSet Research Systems Inc. (FDS), a $10.2 billion market cap financial data and enterprise solutions provider, has experienced a significant downturn in its stock performance. Over the last 52 weeks, FDS shares have plummeted by 44.3%, a stark contrast to the S&P 500's 11% gain during the same period. This underperformance extended to year-to-date results, with FDS down 43.4% compared to the S&P 500's 14% return.

The recent decline was exacerbated by a mixed Q4 earnings release on September 18, which saw FDS shares drop 10.4%. While revenue climbed 6.2% year-over-year to $596.9 million, beating estimates, the company's adjusted operating margin contracted by 200 basis points, and adjusted earnings per share of $4.05 missed analyst expectations. These results dampened investor confidence in the financial technology firm.

Looking ahead, analysts project a modest 1.9% year-over-year EPS growth to $17.30 for fiscal 2026. The stock's outlook remains mixed, with a consensus 'Hold' rating from 19 analysts, comprising two 'Strong Buy,' 10 'Hold,' and seven 'Strong Sell' recommendations. However, UBS Group AG recently upgraded FDS to 'Buy' with a $425 price target, signaling a potential 53.3% upside from current levels.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
FactSet stock has significantly underperformed due to a 44.3% decline over the past 52 weeks, influenced by mixed Q4 earnings and declining operating margins.
In Q4, FactSet's revenue rose 6.2%, but adjusted operating margins decreased, and adjusted EPS fell short of analyst expectations.
The consensus among 19 analysts covering FactSet is a 'Hold' rating, with a mean price target suggesting potential upside.

Read more news on

Business and Economyside-arrow

You may also like

Newmont Stock Soars: Analysts Predict Gold Boom

20 Dec • 43 reads

article image

Wiley Partners with IQVIA for Streamlined Clinical Trials

9 Dec • 72 reads

article image

Stocks Surge: Nasdaq Hits 1.5-Week High on Chip & AI Boost

4 Dec • 151 reads

article image

AI Boom: BofA Warns Investors of Coming Turbulence

4 Dec • 71 reads

article image

Gilead Sciences Shines as Dividend Champ Amid Biopharma Slump

17 Nov • 161 reads

article image